Fig. 3

Knockdown of HSP72 retards the effect of baicalin on the treatment of COPD. Cells were treated with CSE, CSE + baicalin, CSE + baicalin + si-NC, or CSE + baicalin + si-HSP72. Mice were treated with CS + LPS, CS + LPS + baicalin, or CS + LPS + baicalin + CCT251236. a The expression of HSP72 normalized to GAPDH was detected by immunoblotting in cells; *p < 0.05, **p < 0.01, ***p < 0.001 compared to untreated cells; ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 compared to cells treated with CSE + baicalin + si-NC. b The viability of the above cells was determined by CCK-8; *p < 0.05, **p < 0.01, ***p < 0.001 compared to untreated cells; ^#p < 0.05, ^##p < 0.01, ^###p < 0.001 compared to cells treated with CSE; ^&p < 0.05, ^&&p < 0.01, ^&&& p < 0.001 compared to cells treated with CSE + baicalin + si-NC. c Flow cytometry was used to analyze apoptosis of the cells. d Release of inflammatory factors IL-6, IL-8 and TNF-α was measured by ELISA